SCIENCE

Your promising partner CellabMED

CLM-103

Project Target Indication Development phase
CLM-103 IL13Rα2 Glioblastoma multiforme Phase 1

Summary

CLM-103 is a CAR-T cell therapy that recognizes and kills cancer cells expressing IL-13Rα2 protein. IL-13Rα2 is overexpressed in a variety of solid tumors, including malignant glioblastoma but is rarely expressed in normal organs. The antigen-binding domain of CLM-103 is designed to allow intravenous administration by lowering the affinity for IL-13Rα1 expressed in normal cells while binding to the cancer antigen IL-13Rα2. CLM-103 specifically kills cancer cell lines expressing IL-13Rα2, and has shown anticancer efficacy following intravenous administration and then crossing the blood-brain barrier to treat glioblastoma in animals. Phase 1 clinical trial is currently underway on domestic patients with glioblastoma.

Structure and mechanism of action

CLM-103 (YYB-103) uses a modified IL-13 to recognize IL-13Rα2 as its antigen binding domain. It lowers the binding and toxicity to IL-13Rα1 expressed in normal cells through amino acid substitution of IL-13, while maintaining the anticancer activity against IL-13Rα2, therefore achieving anticancer treatment through intravenous administration.

Technical advantage

- CLM-103 is designed to attack only cancer cells without affecting normal cells through CAR structure optimization.

- Since CLM-103 has high selectivity for the cancer antigen IL-13Rα 2, it is safe even during systemic exposure.

- CLM-103 can be delivered to the tumor site, even across the blood-brain barrier, by convenient intravenous administration.

Patent

Project Application/Registration No. Status Name of invention Application date Domestic/Foreign Right holder
*Technical transfer
CLM-103 10-2011789 Registration Chimeric antigen receptors, and T cells in which chimeric antigen receptors are expressed 2017.12.08 South Korea CellabMED
10975148 Registration 2018.02.05 US CellabMED
3333264 Registration 2018.02.13 Europe CellabMED
JP6751493 Registration 2018.02.02 Japan CellabMED
RU2724738 Registration 2018.03.05 Russia CellabMED
AU2016301932 Registration 2018.02.07 Australia CellabMED
MX/2021/15115 Registration 2018.02.02 Mexico CellabMED
ZL 2016800457264 Registration 2018.03.01 China CellabMED
2994797 Registration 2018.02.05 Canada CellabMED
JP 4509069 Registration 2018.02.01 Israel CellabMED

Research paper

Project Journal Year of publication Title of publication Link information Presentation data
CLM-103 Front Immunol. 2021 Nov Chimeric Antigen Receptor T Cells With Modified Interleukin-13 Preferentially Recognize IL13Rα2 and Suppress Malignant Glioma: A Preclinical Study.

Presentation at academic conference

Project Academic conference Title of publication
CLM-103 ASGCT 2017 IL13Rα2-Specific CAR-T Cells Directed to GBM Suppress Tumor Growth in a Mouse Glioma Model
CLM-103 ASGCT 2018 IL13Rα2-CAR T Cells Persist for up to 21 Days after Systemic Administration in Mouse Glioma Models